Alto Neuroscience ANRO ALTO-207 — Direct external program expenses:
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's alto-207 — direct external program expenses:.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's ALTO-207 — direct external program expenses:?
- Alto Neuroscience (ANRO) reported ALTO-207 — direct external program expenses: of $4.14M in Q1 2026.
- What does ALTO-207 — direct external program expenses: mean?
- This metric represents the direct, third-party costs incurred specifically for the research and development of the ALTO-207 clinical program. It captures external expenditures such as contract research organization fees, clinical trial site costs, and manufacturing expenses directly attributable to advancing this specific therapeutic candidate. Tracking these costs allows investors to assess the capital allocation and investment intensity dedicated to this individual asset within the company's broader clinical pipeline.